Robert W. Duggan, Co-Chief Executive Officer of Summit Therapeutics Inc. (SMMT), acquired 3,810,000 shares of the company on June 12, 2026. The transaction, valued at approximately $49.99 million at an average price of $13.12 per share, represents a significant investment by a key executive.
This purchase by Mr. Duggan, a senior officer of Summit Therapeutics, is often viewed by the market as a signal of strong confidence in the company's future prospects and operational performance. The substantial size of the transaction underscores this conviction.
The filing also reveals other recent insider buying activity within Summit Therapeutics. On June 4, 2026, Mr. Duggan purchased an additional 100,000 shares, while Mahkam Zanganeh and Manmeet Singh Soni also made smaller share acquisitions on the same date.